[Therapeutic approaches in symptomatic hypertrophic obstructive cardiomyopathy] (Q77166058)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11707242 AND SRC:MED&resulttype=core&format=json

3 December 2019

review article

1 reference

title

[Therapeutic approaches in symptomatic hypertrophic obstructive cardiomyopathy] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11707242 AND SRC:MED&resulttype=core&format=json

hypertrophic obstructive cardiomyopathy

3 December 2019

main subject

0 references

author name string

A M Montijano Cabrera

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11707242 AND SRC:MED&resulttype=core&format=json

3 December 2019

B Bouzas Zubeldía

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11707242 AND SRC:MED&resulttype=core&format=json

3 December 2019

M Penas Lado

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11707242 AND SRC:MED&resulttype=core&format=json

3 December 2019

W J McKenna

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11707242 AND SRC:MED&resulttype=core&format=json

3 December 2019

publication date

1 November 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11707242 AND SRC:MED&resulttype=core&format=json

Revista Española de Cardiología

3 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11707242 AND SRC:MED&resulttype=core&format=json

3 December 2019

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11707242 AND SRC:MED&resulttype=core&format=json

3 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11707242 AND SRC:MED&resulttype=core&format=json

3 December 2019

page(s)

1311-1326

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11707242 AND SRC:MED&resulttype=core&format=json

Asymmetrical hypertrophy of the heart in young adults

3 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Hypertrophic cardiomyopathy. Clinical spectrum and treatment.

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

The management of hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

[Sudden death (V). Identification and treatment of patients with hypertrophic cardiomyopathy at risk of sudden death]

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Hypertrophic cardiomyopathy: is a left ventricular outflow tract gradient a major prognostic determinant?

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Exercise performance after septal myotomy and myectomy in patients with obstructive hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

[The clinical practice guidelines of the Sociedad Española de Cardiología on cardiomyopathies and myocarditis]

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

EFFECTS OF BETA ADRENERGIC BLOCKADE ON THE CIRCULATION WITH PARTICULAR REFERENCE TO OBSERVATIONS IN PATIENTS WITH HYPERTROPHIC SUBAORTIC STENOSIS

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta-Adrenergic Blockade

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Chronic beta adrenergic receptor blockade in the treatment of idiopathic hypertrophic subaortic stenosis

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Propranolol in management of muscular subaortic stenosis

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Long-term propranolol therapy in muscular subaortic stenosis

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effect of acute administration of propranolol on ventricular function in hypertrophic obstructive cardiomyopathy measured by non-invasive techniques

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Treatment of hypertrophic obstructive cardiomyopathy with verapamil

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects.

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Does verapamil improve left ventricular relaxation in patients with myocardial hypertrophy?

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effect of verapamil on systolic and diastolic coronary blood flow velocity in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effects of diltiazem on left ventricular diastolic behavior in patients with hypertrophic cardiomyopathy: evaluation with exercise pulsed Doppler echocardiography

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effects of sublingual nifedipine on hemodynamics and systolic and diastolic function in patients with hypertrophic cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effects on left ventricular function of pindolol added to verapamil in hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Haemodynamic effects of nifedipine and propranolol in patients with hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Amiodarone for long-term management of patients with hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Diffuse muscular subaortic stenosis: Surgical treatment

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Hypertrophic obstructive cardiomyopathy: ten- to 21-year follow-up after partial septal myectomy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Surgical treatment of hypertrophic obstructive cardiomyopathy with special reference to complications and to atypical hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Current operative treatment of obstructive hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Postoperative and long-term prognosis of myotomy-myomectomy for obstructive hypertrophic cardiomyopathy: influence of associated mitral valve replacement

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Comparison of ventricular septal surgery and mitral valve replacement for hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Hypertrophic obstructive cardiomyopathy. Initial results and long-term follow-up after Morrow septal myectomy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy.

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Management of symptomatic hypertrophic obstructive cardiomyopathy--long-term results after surgical therapy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Long-lasting improvement after septal myectomy for hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Septal myomectomy and mitral valve replacement for idiopathic hypertrophic subaortic stenosis: short- and long-term follow-up

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Hemodynamic findings in patients with left bundle branch block after myectomy in hypertrophic obstructive cardiomyopathy (HOCM)

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Aortic regurgitation: a common complication after surgery for hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Results of operation for coexistent obstructive hypertrophic cardiomyopathy and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Clinical and hemodynamic results after mitral valve replacement in patients with obstructive hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Long-term Clinical and Echocardiographic Follow-up After Surgical Correction of Hypertrophic Obstructive Cardiomyopathy With Extended Myectomy and Reconstruction of the Subvalvular Mitral Apparatus

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Extended myectomy for hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Permanent pacing as treatment for hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effects of permanent dual-chamber pacing on mitral regurgitation in hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler echocardiographic and catheterization hemodynamic study

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Effects of dual-chamber pacing in hypertrophic cardiomyopathy on left ventricular outflow tract obstruction and on diastolic function

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY).

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: too soon for a rush to judgment?

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

[ [In Process Citation]

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Influence of right ventricular pacing site on left ventricular outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Pacing in hypertrophic obstructive cardiomyopathy: A randomized crossover study

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up. PIC study group. Pacing In Cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points.

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Results of permanent dual-chamber pacing in symptomatic nonobstructive hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Transcoronary chemical ablation of ventricular tachycardia

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

New treatment methods for patients with hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: Acute Results and 3-Month Follow-Up in 25 Patients

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Alcohol septal ablation in hypertrophic obstructive cardiomyopathy: the need for a registry

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Advances in molecular genetics and management of hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Five years of percutaneous transluminal septal myocardial ablation

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Multiple disease genes cause hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

Hypertrophic Cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016/S0300-8932(01)76502-5

7 January 2021

10.1016/S0300-8932(01)76502-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11707242 AND SRC:MED&resulttype=core&format=json

3 December 2019

1 reference